Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis

Diabetes, Obesity and Metabolism

Volumn 11, Issue 4, 2009, Pages 372-378

  Monami, M ^a   Marchionni, N ^a   Mannucci, Edoardo ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Glycaemic control; Insulin analogues

Indexed keywords

HEMOGLOBIN A1C; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; LONG ACTING DRUG; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; LONG ACTING INSULIN;

ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INCIDENCE; INFORMATION RETRIEVAL; INSULIN DEPENDENT DIABETES MELLITUS; MEDLINE; META ANALYSIS; RISK REDUCTION; SIDE EFFECT; SYSTEMATIC REVIEW; WEIGHT GAIN; ADOLESCENT; ADULT; BLOOD; CHEMICALLY INDUCED; CHILD; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 1; METABOLISM; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADOLESCENT; ADULT; BODY MASS INDEX; CHILD; DIABETES MELLITUS, TYPE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN, ISOPHANE; INSULIN, LONG-ACTING; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 61549118211     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.00976.x     Document Type: Article

References (25)

1. Valensi P, Cosson E. Is insulin detemir able to favor a lower variability in the action of injected insulin in diabetic subjects? Diabetes Metab 2005; 31: 4S34-4S39.
2. Peterson GE. Intermediate and long-acting insulins: A review of NPH insulin, insulin glargine and insulin detemir. Curr Med Res Opin 2006; 22: 2613-2619.
3. Chatterjee S, Jarvis-Kay J, Rengarajan T, Lawrence IG, McNally PG, Davies MJ. Glargine versus NPH insulin: Efficacy in comparison with insulin aspart in a basal bolus regimen in type 1 diabetes -the glargine and aspart study (GLASS) a randomised cross-over study. Diabetes Res Clin Pract 2007; 77: 215-222.
4. Kudva YC, Basu A, Jenkins GD, et al. Randomized controlled clinical trial of glargine versus ultralente insulin in the treatment of type 1 diabetes. Diabetes Care 2005; 28: 10-14.
5. Porcellati F, Rossetti P, Pampanelli S, et al. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin. Diabet Med 2004; 21: 1213-1220.
6. Home P, Bartley P, Russell-Jones D, et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: A randomized clinical trial. Diabetes Care 2004; 27: 1081-1087.
7. Pieber TR, Treichel HC, Hompesch B, et al. Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy. Diabet Med 2007; 24: 635-642.
8. De LI, Vague P, Selam JL, et al. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 2005; 7: 73-82.
9. Home PD, Rosskamp R, Forjanic-Klapproth J, Dressler A. A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes. Diabetes Metab Res Rev 2005; 21: 545-553.
10. Raskin P, Klaff L, Bergenstal R, Halle JP, Donley D, Mecca T. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 2000; 23: 1666-1671.
11. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of insulin glargine in type 1 diabetes. Diabetes Care 2000; 23: 639-643.
12. Kolendorf K, Ross GP, Pavlic-Renar I, et al. Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in type 1 diabetes. Diabet Med 2006; 23: 729-735.
13. Robertson KJ, Schoenle E, Gucev Z, Mordhorst L, Gall MA, Ludvigsson J. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes. Diabet Med 2007; 24: 27-34.
14. Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther 2004; 26: 724-736.
15. Schober E, Schoenle E, Van DJ, Wernicke-Panten K. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2002; 15: 369-376.
16. Standl E, Lang H, Roberts A. The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes. Diabetes Technol Ther 2004; 6: 579-588.
17. Vague P, Selam JL, Skeie S, et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003; 26: 590-596.
18. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996; 17: 1-12.
19. Radman M, Jurisic D, Ljutic D, Jerkovic R, Kovacic N, Hozo IS. Assessing glycemia in type 1 diabetic patients using a microdialysis system for continuous glucose monitoring. Ann Saudi Med 2007; 27: 166-170.
20. Hassan K, Rodriguez LM, Johnson SE, Tadlock S, Heptulla RA. A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes. Pediatrics 2008; 121: E466-e472.
21. Novo-Nordisk web site. http://www.clinicalstudyresults.org. 2008.
22. Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007: CD005613.
23. Mullins P, Sharplin P, Yki-Jarvinen H, Riddle MC, Haring HU. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus. Clin Ther 2007; 29: 1607-1619.
24. Hermansen K, Davies M, Derezinski T, Martinez RG, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006; 29: 1269-1274.
25. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008; 51: 408-416.